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Pancreas allograft acceptance is markedly more selec-
tive than other solid organs. The number of pancreata
recovered is insufficient to meet the demand for pan-
creas transplants (PTx), particularly for patients await-
ing simultaneous kidney-pancreas (SPK) transplant.
Development of a pancreas donor risk index (PDRI) to
identify factors associated with an increased risk of
allograft failure in the context of SPK, pancreas after
kidney (PAK) or pancreas transplant alone (PTA), and
to assess variation in allograft utilization by geogra-
phy and center volume was undertaken. Retrospective
analysis of all PTx performed from 2000 to 2006 (n =
9401) was performed using Cox regression controlling
for donor and recipient characteristics. Ten donor vari-
ables and one transplant factor (ischemia time) were
subsequently combined into the PDRI. Increased PDRI
was associated with a significant, graded reduction
in 1-year pancreas graft survival. Recipients of PTAs
or PAKs whose organs came from donors with an el-
evated PDRI (1.57–2.11) experienced a lower rate of
1-year graft survival (77%) compared with SPK trans-
plant recipients (88%). Pancreas allograft acceptance
varied significantly by region particularly for PAK/PTA
transplants (p < 0.0001). This analysis demonstrates
the potential value of the PDRI to inform organ accep-
tance and potentially improve the utilization of higher
risk organs in appropriate clinical settings.
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Introduction
Appropriate allograft selection is widely viewed as a key
component to successful pancreatic transplantation (PTx)
(1). Historically, fear of early graft loss from technical failure
has resulted in very conservative organ acceptance prac-
tices. Unfortunately, the supply of high-quality, brain dead
donors appears to be decreasing and consequently, there
has been a reduction in the overall number of PTx per-
formed, from a high of 1484 transplants in 2004 to 1331 in
2007, despite a significant waiting list of diabetic patients
and data substantiating the value of PTx, particularly when
combined with kidney transplantation (2).
Methods of systematic, quantitative assessment of donor
quality have been developed for kidney (KDRI) (3) and liver
(LDRI) donors (4). These donor risk indexes (DRIs) include
factors which can be identified at the time of organ alloca-
tion that also predict the risk of early graft failure and are
combined into a continuous scale. A DRI is derived from
retrospective registry analyses that control for donor, recip-
ient and transplant-related factors (such as HLA matching
and cold ischemia time) and account for interactions lead-
ing to increased risk of graft loss.
PTx is performed in three distinct clinical scenarios: simul-
taneous kidney-pancreas (SPK) transplantation , pancreas
after kidney (PAK) transplantation and pancreas transplant
alone (PTA). Previous reports have demonstrated that the
risk of allograft failure is higher in solitary PTx (PAK and
PTA) versus SPK transplants. Since a DRI-like assessment
has never been developed for pancreas transplantation,
there are no prior data available to discern whether there
is a differential effect of graft quality on transplant outcome
as a function of the PTx type. Furthermore, unlike kidney
transplantation in which certain recipient factors alone pro-
vide useful information as to when to use a high risk organ,
there is no equivalent dataset to guide use of high-risk pan-
creas allografts for specific patient populations who might
benefit from higher risk organs.
Previous reports have demonstrated substantial variation
in the proportion of pancreas allografts that are recov-
ered and transplanted as a function of region and organ
procurement organization (OPO) practice (5). These differ-
ences may reflect center practice, local allocation systems
which discourage the use of higher risk organs or variation
in donor quality. A more precise characterization of the
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degree of regional variation may be useful in examining
current allocation practices to ensure that all appropriate
and beneficial organs are utilized.
This paper describes the construction of a pancreas allo-
graft PDRI based on data from SPK, PAK and PTA trans-
plants. The PDRI was used to assess the differential im-
pact of organ quality on PTx outcomes within each of the
three clinical scenarios, and as a function of the type of
transplant and recipient severity of illness. The PDRI was
also used to examine the variation in organ recovery and
transplantation practices within the United States.
Methods
Data source
Data from the Scientific Registry of Transplant Recipients were reviewed
for all patients undergoing SPK (n = 6248), PTA (n = 780) or PAK (n = 2373)
from January 1, 2000 to January 31, 2006. Demographic and transplant
characteristics for recipients and donors were determined for all transplants
(Table 1A and B). Graft failure was determined by center reporting on the
pancreas follow-up forms and included patient death (Figure 1). All patients
undergoing these transplants >18 years of age were included.
Model development
A Cox regression model was fit using all available donor, recipient and
transplant factors to assess the risks of graft failure at 1 year. The model
was stratified by transplant type in order to allow differing failure rates for
each type of PTx. A likelihood ratio test was performed to assess whether
the coefficients differed by strata; a significant difference was not found
(p = 0.85). In addition, several interactions between transplant type and
clinically relevant donor and recipient characteristics were also examined.
Significant interactions were found between transplant type and recipient
age, and between PAK and cerebrovascular accident (CVA) as donor cause
of death. The index of concordance for the final 1-year graft failure model
was 0.67.
Recipient factors in the model included transplant type, age, race, sex, body
mass index (BMI), panel reactive antibody (PRA), presence of peripheral
vascular disease, primary payment type, albumin and previous transplant.
Transplant specific factors included transplant center, duct management,
degree of HLA matching, preservation time and transplant year.
Donor factors in the model included: age, sex, race, BMI, height, cause of
death, donation after cardiac death (DCD) and serum creatinine. Additional
donor variables were considered and excluded based on their lack of associ-
ation with outcomes including: amylase, lipase, serum glutamic oxaloacetic
transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), dura-
tion of downtime, time of flush solution, smoking, cocaine use, alcohol use,
hypertension, sodium and viral serologies. However, the absence of asso-
ciations with these factors may reflect incomplete data recording as well
as existing clinical practice, which limits the use of organs with significantly
abnormal laboratory values.
Determination of the DRI
Donor and transplant specific factors, including ischemia time, which were
statistically significantly associated with graft failure in the survival model,
were used to construct the DRI. The appropriate coefficients were then
combined in an index such that the ‘median’ donor had a DRI of 1.0. In-
creasing DRI is associated with a higher risk of graft failure, so that the
DRI can be interpreted as a risk ratio comparing the donor at hand with the
median risk donor. The median donor is defined as male, 28 years of age,
non-black, non-Asian, BMI of 24, height of 173 cm, non-CVA/stroke as the
cause of death, pancreas preservation time of 12 h, non-DCD and serum
creatinine less than 2.5 mg/dL. For the purpose of allocation and regional
comparisons, cold ischemia time was fixed at 12 h for all donors.
Definition of high and median risk recipient
To determine the differential effect of organ quality in recipients of median
and high risk, two recipient profiles were determined. The median risk
recipient was 41 years old, BMI of 25, male, white, albumin 3.7 gm/dL,
PRA = 0, private insurance, no prior PTx and enterically drained. The high
risk recipient was defined as age >50, BMI >30, female, PRA = 20, with
all other characteristics held constant.
Statistical analyses
All calculations were performed using SAS version 9.1.3 (SAS Institute Inc.,
Cary, NC). A p-value of 0.05 was considered significant and differences
were assessed using parametric and nonparametric statistical tests as
appropriate.
IRB approval
This project was approved by HRSA’s SRTR project officer. HRSA has deter-
mined that this study satisfies the criteria for the IRB exemption described
in the ‘Public Benefit and Service Program’ provisions of 45 CFR 46.101(b)
(5) and HRSA Circular 03.
Results
The PDRI includes 10 donor and one transplant character-
istic (Table 2). Donor factors include donor sex, age, black
race, Asian race, BMI, cause of death, creatinine, height
and DCD status. The transplant factors include pancreas
preservation time and an interaction between PAK and the
donor cause of death. Among the donor factors examined,
age, BMI and DCD status appeared to have the greatest
impact on risk. For example, increasing donor age from 28
to 45, holding all other factors constant, was associated
with a 56% increase in risk (PDRI increases from 1.0 to
1.56). Similarly, a DCD donor was associated with a rela-
tive risk of graft failure of 1.39 compared to a brain dead
donor.
Increasing PDRI was associated with a significant increase
in graft loss within the first year posttransplant for all types
of PTx (Figure 2). Among average risk recipients, there
appeared to be a differential risk of graft loss associated
with high PDRI organs that were used in solitary PTx as
compared with SPKs (Tables 3 and 4). PTx in average risk
recipients, using donors with a PDRI between 1.57 and
2.11, had a 1-year graft survival of 83% following SPK ver-
sus 77% for PAK or PTA. Those pancreas survival rates are
consistent with the national averages published from SRTR
analyses. The cause of failure appeared similar across PDRI
categories for SPK recipients (Table 5B). In the isolated PTx
recipients (PAK/PTA), however, there was a trend toward
higher rates of technical early loss among recipients of high
PDRI organs (p = 0.08) (Table 5A).
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Table 1: Donor and recipient characteristics of pancreas transplants (1/1/2000–12/31/2006)
Transplant type
All (n = 9401) KP (n = 6248) PAK (n= 2373) PTA (n = 780)
n % n % n % n %
(A) Donor charaterstics
Donor gender male 6331 67.3 4226 67.64 1600 67.4 505 64.7
Donor race 6751 71.8 4408 70.55 1765 74.4 578 74.1
White
Black or African American 1235 13.1 894 14.31 257 10.8 84 10.8
Hispanic/Latino 1193 12.7 797 12.76 301 12.7 95 12.2
Other 86 0.9 52 0.83 18 0.8 16 2.0
Donor cause of death
Anoxia 833 8.9 537 8.59 214 9.0 82 10.5
Cerebrovascular/stroke 1958 20.8 1271 20.34 517 21.8 170 21.8
Head trauma 6366 67.7 4271 68.36 1588 66.9 507 65.0
CNS tumor 64 0.7 44 0.7 13 0.6 7 0.9
Other 178 1.9 125 2 40 1.7 13 1.7
DCD 128 1.4 87 1.39 22 0.9 19 2.4
Donor SCr >2.5 162 1.7 66 1.06 75 3.2 21 2.7
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Donor age 9401 26.3 (10.8) 6248 26.5 (10.8) 2373 25.7 (10.5) 780 26 (10.9)
Donor BMI 9391 24 (4.2) 6243 24 (4.1) 2368 24.1 (4.1) 780 24.2 (4.3)
Donor’s height (cm) 9398 172.6 (11.7) 6246 172.7 (11.7) 2372 172.4 (11.8) 780 172.1 (11.9)
Donor’s weight (kg) 9401 72.1 (15.9) 6248 72.1 (15.8) 2373 72.1 (16) 780 72.1 (16.1)
Donor serum amylase 9222 133.7 (234.8) 6122 133 (239.8) 2338 134.1 (222.8) 762 138.6 (229.9)
Donor serum lipase 8896 75 (141.5) 5918 77.4 (142.4) 2254 66.1 (123.8) 724 82.9 (180.1)
Donor serum creatinine 9372 1.05 (0.89) 6229 1 (0.9) 2366 1.1 (0.9) 777 1.1 (1)
(B) Recipient charaterstics
Recipient gender male 5459 58.1 3793 60.71 1352 57.0 314 40.3
Recipient race 7613 81.0 4811 77 2051 86.4 751 96.3
White
Black or African American 1032 11.0 850 13.6 171 7.2 11 1.4
Asian 71 0.8 57 0.91 13 0.6 1 0.1
Other 74 0.8 56 0.9 15 0.6 3 0.4
Candidate PVD 693 7.4 435 6.96 217 9.1 41 5.3
Recipient previous PA transplant 720 7.7 98 1.57 538 22.7 84 10.8
Recipient peak PRA
0–9 7518 80.0 5075 81.23 1832 77.2 611 78.3
10–80 1513 16.1 943 15.09 445 18.8 125 16.0
80–100 351 3.7 217 3.47 90 3.8 44 5.6
Recipient primary payment private 4830 51.4 3021 48.35 1180 49.7 629 80.6
Duct management noncystostomy 1820 19.4 945 15.12 605 25.5 270 34.6
N Mean (SD) N Mean (SD) N Mean (SD) N Mean (SD)
Recipient age 9401 41.1 (8.2) 6248 40.9 (8.3) 2373 41.7 (7.7) 780 40.7 (9.6)
Recipient BMI 8291 25 (4.2) 5513 24.8 (4.1) 2072 25.2 (4.3) 706 25.5 (4.3)
Recipient’s height (cm) 8541 170.3 (10.4) 5677 170.8 (10.5) 2131 169.7 (10.1) 733 168.4 (10.2)
Recipient’s weight (kg) 8762 72.8 (15.3) 5810 72.7 (15.2) 2214 72.9 (15.2) 738 72.7 (15.8)
Recipient years since DM onset 8314 26.8 (8.3) 5500 26.5 (8) 2088 28.3 (7.8) 726 25.3 (10.9)
Pancreas preservation time 7415 13.6 (5.8) 4902 13.1 (5.7) 1883 14.1 (5.9) 630 15.4 (5.7)
Nationally, there was a significant difference between
the PDRI of pancreata recovered but not transplanted
(PDRI interquartile range of 1.03– 2.02) and accepted
(PDRI interquartile range of 0.84–1.32) for transplantation
(p < 0.001). There was no significant difference in the PDRI
of organs used for SPK transplants (median = 1.01) com-
pared to that used in isolated PAK/PTA transplants (me-
dian = 0.99) (p = 0.09). Interestingly, despite the ongoing
need for organs, the use of marginal pancreas donors ap-
pears to be declining nationally. In 2000, the 75th percentile
PDRI was 1.38 for transplants that decreased to 1.31 in
2006. The majority of this decline occurred in the PAK/PTA
transplants in which the 75th percentile PDRI decreased
from 1.43 to 1.25 (p < 0.001 for trend), while there was
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Figure 1: Kaplan–Meier survival analysis of pancreas allograft
survival following simultaneous kidney-pancreas transplant
(SPK), pancreas after kidney transplant (PAK) and pancreas
transplant alone (PTA) among patients transplanted between
2000 and 2006. Allograft survival is adjusted for donor, recipient
and transplant characteristics.
minimal difference in the SPK transplants—1.36–1.33 (p =
0.29 for trend).
Examining the most recent 2.5 years of our cohort (July
2004–December 2006), several UNOS regions were iden-
tified as being aggressive in their utilization of pancreas
allografts (Table 6). The 75th percentile of PDRI of all types
of PTx performed in regions 7 (1.47; p < 0.001 vs. national),
10 (1.44; p < 0.001 vs. national), 9 (1.37; p = 0.34 vs. na-
tional) and 1 (1.36; p = 0.13 vs. national) were all above
the national 75th percentile of 1.30. By comparison, region
6 had the lowest 75th percentile PDRI (1.14; p = 0.07 vs.
national). Differences by region were even greater in the
utilization of allografts for SPK. The most aggressive region
had a 75th percentile PDRI of 1.50 (p < 0.001 vs. national)
compared to a PDRI of 1.05 (p = 0.007 vs. national) in
the least aggressive region. Overall utilization of pancreas
donors with PDRI of 1.16–1.56 varied from a high of 83%
in region 10 to a low of 38% in region 1.
Utilization of higher risk PTx allografts was also corre-
lated with center activity (Table 6). The 75th percentile
PDRI among centers performing less than 10 PTx over 2.5
years was 1.19 for SPK transplants and 1.21 for solitary
(PAK/PTA) transplants. For centers performing >40 trans-
plants in 2.5 years, the 75th percentile PDRI was 1.42 for
SPKs (p < 0.01 vs. national average) and 1.33 for solitary
PTx (p = NS compared with national average).
Discussion
The PDRI is a measure of allograft quality that predicts the
risk of allograft failure at 1 year. The PDRI can be calculated
from donor and transplant characteristics that are available
at the time of organ offer and may potentially guide organ
acceptance and allocation decisions. Furthermore, it ap-
pears that for recipients with median characteristics there
is a differential effect of PDRI as a function of transplant
type, in that graft outcome is worse for solitary PTx than
SPK for poor quality organs. Furthermore, potentially use-
able allografts appear not to have been transplanted in re-
gions without higher volume, aggressive PTx centers.
Prior retrospective analyses have identified a number of
donor and transplant related factors which appear to be
correlated with worse outcome following pancreas trans-
plantation. Technical failure, defined as early graft loss due
to nonimmune related factors (such as venous thrombo-
sis), is responsible for the vast majority of pancreas graft
loss within the first year posttransplant (6). Retrospective
analyses from the University of Minnesota found that the
overall rate of graft loss due to technical failure at a mean
follow-up of 45 months ranged from 30.6% for SPK to
37.9% for PTA. The most common causes of technical fail-
ure were thrombosis (52%), infection (19%), pancreatitis
Table 2: Summary of pancreas DRI
Reference donor Change factor
Donor characteristics (DRI = 1.00) value to DRI
Gender Male Female 0.87
Age 28 45 1.56
Black race No Yes 1.27
Asian race No Yes 1.17
BMI 24 30 1.17
Height (cm) 173 190 0.9
Cause of death: CVA/stroke No Yes 1.23
Cause of death: CVA/stroke in PAK No Yes 0.93
Pancreas preservation time (h) 12 20 1.13
DCD No Yes 1.39
SCr > 2.5 No Yes 1.22
Equation: pDRI = exp(–0.13792 × I [Female Donor)]–0.034455 × I[Donor Age <20] × [Donor Age –20] + 0.026149 × [Donor Age –28] +
0.19490 × I [Donor Creatinine >2.5] + 0.23951 × I[Donor Black Race] + 0.15711 × I[Donor Asian Race] − 0.000986347 × [Donor BMI
−24] + 0.033274 × I[Donor BMI >25] × [Donor BMI − 25] −.006073879 × (Donor Height −173) + 0.21018 × I [Donor COD CVA]
−0.28137 × I [Donor COD CVA for PAK txp] + 0.014678 × [Preservation Time −12] + 0.33172 × I [DCD])
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Figure 2: (A) Adjusted 1-year graft survival following simultaneous kidney-pancreas (SPK) transplant as a function of the pancreas
donor risk index (PDRI). Curves shown reflect expect survival for an average recipient (41 years old, BMI = 25, male, white, albumin 3.7
gm/Dl PRA = 0, private insurance, no prior PTx and enterically drained) transplanted with pancreata from each PDRI strata. (B) Adjusted
1-year graft survival following pancreas after kidney (PAK) transplant as a function of the pancreas donor risk index (PDRI). Curves shown
reflect expect survival for an average recipient (41 years old, BMI = 25, male, white, albumin 3.7 gm/Dl PRA = 0, private insurance, no
prior PTx and enterically drained) transplanted with pancreata from each PDRI strata. (C) Adjusted 1-year graft survival following pancreas
transplant alone (PTA) as a function of the pancreas donor risk index (PDRI). Curves shown reflect expect survival for an average recipient
(41 years old, BMI = 25, male, white, albumin 3.7 gm/Dl PRA = 0, private insurance, no prior PTx and enterically drained) transplanted
with pancreata from each PDRI strata.
(20%) and intestinal leak (6.5%). A number of donor factors
were found to correlate with technical failure, including in-
creased BMI (> 30 kg/m2), prolonged preservation time (>
24 h) and nontrauma death. Interestingly, neither age of the
donor nor type of transplant (SPK vs. PAK/PTA) correlated
with graft loss.
The use of older donors for SPK transplants has been re-
cently examined using UNOS registry data and survival
modeling (7). Salvalaggio et al. found a higher rate of graft
loss in SPK recipients associated with donors > 45 years
of age compared to younger donors. At 5 years, the death-
censored pancreas graft survival in SPK recipients using
younger donors was 80.1% versus 71.3% for older donors;
patient survival was similar with 5-year survival rates of
84.5% for young donors and 81.0% for older donors. By
comparison, the 5-year survival rate of patients wait-listed
for SPKs was only 45.4%. In this analysis, acceptance of
an older donor organ rather than remaining on the waiting
list was associated with improved survival if the expected
wait for a young donor exceeded 1.5 years. Median waiting
time for a young donor in the United States was approxi-
mately 547 days. However, there was substantial regional
variation in the percentage of patients receiving a young
donor SPK in this time, from a low of 11.1% in Region
1 to 69% in Region 3. Thus, the authors conclude that
the benefit (and thus utilization) of older donors is likely to
vary by regional allocation practice and donor supply. The
Table 3: Unadjusted 1-year pancreas allograft survival by DRI and transplant type
SPK PAK PTA
Adjusted% 95% Confidence Adjusted% 95% Confidence Adjusted% graft 95% Confidence
DRI group graft survival limits graft survival limits survival limits
0.64–0.85 88 (87, 90) 84 (81, 87) 84 (76, 89)
0.86–1.15 87 (86, 89) 77 (73, 79) 82 (77, 87)
1.16–1.56 82 (79, 84) 75 (70, 79) 70 (61, 77)
1.57–2.11 78 (75, 81) 69 (61, 75) 68 (57, 77)
2.12–2.86 77 (70, 82) 67 (46, 81)
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Table 4: Adjusted 1-year pancreas allograft survival by DRI and transplant type. Adjusted for recipient characteristics (median/mode
recipient)
SPK PAK PTA
Adjusted% graft 95% Confidence Adjusted% graft 95% Confidence Adjusted% 95% Confidence
DRI group survival limits survival limits graft survival limits
0.64–0.85 91 (89, 93) 89 (86, 92) 88 (83, 93)
0.86–1.15 90 (89, 92) 83 (80, 86) 88 (84, 92)
1.16–1.56 86 (83, 88) 81 (77, 85) 78 (71, 86)
1.57–2.11 83 (80, 87) 77 (71, 84) 77 (69, 86)
2.12–2.86 82 (77, 87) — (—,—) — (—,—)
successful use of older donors has also been considered
in single center experiences. Data from Wake Forest Medi-
cal Center demonstrated no difference in pancreas allograft
survival at 29 months between conventional donors (80%
vs. 79%) and extended donors (age <10 or >45) (8). In
contrast, strong associations between donor age and graft
survival were observed in the current and previous registry
analyses; this discrepancy may be related to center selec-
tion and management practices that permit the successful
use of pancreata from older donors as well as the greater
number of cases available for analysis.
The other source of potential expansion of the donor pool,
donation after cardiac death, has also been critically exam-
ined in small series and registry analyses. Early experience
from the University of Wisconsin using DCD donors for
SPKs demonstrated excellent pancreas allograft survival in
DCD donors, despite a higher incidence of delayed graft
function in the renal allograft (9,10). Registry analysis from
transplants performed between 1993 and 2003 confirmed
a growing use of DCD organs. However, by the end of
2003, only 0.1% of all PTxs were from DCDs. Our anal-
ysis of the SRTR database reveals that DCDs now repre-
sent 3.4% of all pancreas donors, demonstrating a growing
comfort with this source of donor organs. In the previous
analysis of registry data through 2002, there were no sig-
nificant differences in pancreas allograft survival at 1, 3
or 5 years between DCD donor organs (92%, 82% and
74%, respectively) and DBD donors (86%, 77% and 70%,
respectively). Acceptance of DCD organs is generally lim-
ited to donors with extubation and flush times of less than
30 min while donor demographic characteristics (age, sex,
BMI) did not differ between the DCD and DBD population.
However, we observed a marginally significant risk asso-
ciated with DCD PTx (HR = 1.39, p = 0.10). Thus, the
comparable unadjusted survival between DCD and DBD
transplants noted in single center studies is likely a conse-
quence of more careful selection of pancreata from DCD
donors and may change as experience grows and organ
selection criteria expand.
Expansion of the pool of available organs for SPK trans-
plantation is crucial to meet demand for transplant and to
keep waiting times for the uremic, diabetic patients to a
minimum (11,12). Evaluation of the benefit of kidney trans-
plantation using the metric of incremental life years from
transplant has confirmed the value of SPK transplantation
(13). When compared to the expected waiting list survival,
SPK transplantation was associated with the greatest in-
crease in expected life years from among all types of renal
transplants. As demonstrated by Salvalaggio et al., the high
waiting list mortality and long waiting time justifies the
Table 5: One-year cause of pancreas graft failure for (A) PTA/PAK and (B) SPK recipients
Among failures not
resulting in death
n (%) Among all
Among all Tx within 1 years –
n (%) failed
failures Total
DRI Group n Txps Tech. Immuno. n (%) due to death Due to death Tech. Immuno. Unknown n (%) failure
(A) PTA/PAK recipients
42 (58) 31 (42) 15 (15) 15 (2) 42 (6) 31 (5) 15 (2) 103 (16)
0.86–1.15 1014 94 (59) 66 (41) 32 (14) 32 (3) 94 (9) 66 (7) 31 (3) 223 (22)
1.16–1.56 522 60 (60) 40 (40) 14 (10) 14 (3) 60 (11) 40 (8) 25 (5) 139 (27)
1.57–2.11 246 40 (74) 14 (26) 9 (12) 9 (4) 40 (16) 14 (6) 14 (6) 77 (31)
2.12–2.86 57 6 (–) 5 (–) 1 (–) 1 (–) 6 (–) 5 (–) 3 (–) 15 (–)
(B) SAK recipients
77 (79) 21 (21) 36 (23) 36 (3) 77 (6) 21 (2) 26 (2) 160 (12)
0.86–1.15 1906 123 (78) 34 (22) 66 (27) 66 (4) 123 (6) 34 (2) 19 (1) 242 (13)
1.16–1.56 1135 90 (74) 31(26) 51 (25) 51 (4) 90 (8) 31 (3) 34 (3) 206 (18)
1.57–2.11 625 68 (77) 20 (23) 30 (22) 30 (5) 68 (11) 20 (3) 17 (3) 135 (22)
2.12–2.86 218 21 (68) 10 (32) 9 (18) 9 (4) 21 (10) 10 (5) 11 (5) 51 (23)
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Table 6: Utilization: Summary of pancreas DRI by region, transplant type and center size (pancreas transplants from 6/30/2004 to
12/31/2006). Transplant-related characteristics (such as pancreas preservation time and donor CVA for PAK) were not used to compute
the DRI for the purpose of evaluating utilization
Transplant type
PAK/PTA SPK
DRI percentiles DRI percentiles DRI percentiles
All N 25th 50th 75th N 25th 50th 75th N 25th 50th 75th
All 3375 0.84 1.00 1.3 1134 0.83 0.99 1.27 2241 0.84 1.01 1.31
Region
1 121 0.85 1.07 1.36 90 0.83 1.03 1.36 31 0.94 1.13 1.41
2 458 0.85 1.03 1.27 174 0.8 0.98 1.17 284 0.89 1.05 1.35
3 403 0.84 0.98 1.23 58 0.82 0.95 1.1 345 0.84 0.99 1.27
4 156 0.81 0.93 1.19 34 0.84 0.96 1.03 122 0.81 0.93 1.22
5 487 0.83 0.95 1.18 117 0.83 0.92 1.08 370 0.83 0.96 1.21
6 95 0.85 0.91 1.14 15 0.89 1.19 1.38 80 0.84 0.91 1.05
7 670 0.85 1.08 1.47 312 0.85 1.05 1.46 358 0.86 1.09 1.5
8 129 0.82 0.92 1.17 24 0.87 1 1.23 105 0.81 0.91 1.15
9 97 0.86 1.02 1.37 41 0.84 0.97 1.21 56 0.88 1.08 1.4
10 444 0.85 1.05 1.44 179 0.84 1.07 1.5 265 0.85 1.03 1.42
11 315 0.82 0.98 1.19 90 0.82 0.93 1.07 225 0.82 1.01 1.22
Transplant type
SPK 2241 0.84 1.01 1.31 — — — — — 0.84 1.01 1.31
PAK 857 0.83 0.98 1.28 — 0.83 0.98 1.28 2 — — —
PTA 277 0.84 0.99 1.24 — 0.84 0.99 1.24 0 — — —
Center size (per last 2.5 years)
<10 233 0.82 0.94 1.19 66 0.82 0.92 1.21 167 0.82 0.95 1.19
10–19 569 0.83 0.96 1.23 157 0.82 1 1.25 412 0.83 0.96 1.23
20–29 486 0.83 0.97 1.23 147 0.82 0.97 1.24 339 0.83 0.98 1.22
30–39 282 0.83 0.97 1.2 78 0.81 0.95 1.12 204 0.84 0.99 1.21
>40 1805 0.85 1.03 1.39 686 0.84 1 1.33 1119 0.86 1.05 1.42
potential increased risk of the use of marginal organs in
this population if the pancreas allograft survival rates can
be maintained (7).
The use of pancreas allografts for solitary transplants (PTA
and PAK) has been far more controversial. In a national
registry analysis, Ventstrom et al. suggested that survival
was actually reduced in patients who received PTA com-
pared to those patients who remain on the waiting list
(14). These findings were challenged by Gruessner et al.
who examined a more contemporary cohort and found no
detrimental effect of PTx on survival (15). However, they
also did not demonstrate a mortality benefit. It should be
noted that 1-year patient survival rates in PTA recipients
are the highest of any solid organ transplant group. Fur-
thermore, pancreas transplantation provides dramatic im-
provements in quality of life (16). Other benefits of PTx,
including the reduction in end organ complications, have
been extrapolated from the Diabetes Control and Com-
plications trial, but have not been definitively proven in
the PTA and PAK population (17). However, given the lim-
ited long-term success of islet transplantation and lack
of good prospective studies, only whole organ PTx can
truly result in sustained euglycemia without significant
hypoglycemia.
The findings of this study, that pancreas allograft failure
differs according to transplant type, should inform clini-
cal decision making and allocation. The effect of changing
donor characteristics can increase the relative risk of graft
failure significantly and represented an absolute decrease
in organ survival of greater than 10% at 1 year for the
highest risk organs (Table 4). Use of donors with higher
PDRI is appropriate and beneficial in the context of an SPK
transplant versus a solitary PTx. Organs used for SPK trans-
plantation have been demonstrated to have overall better
survival and reduced graft loss even at higher PDRIs. PTA
and PAK that use organs from relatively higher PDRI donors
are associated with a slightly higher early technical failure
rate contributing to early graft loss. Our data suggests this
risk may be exacerbated by poor organ quality. Thus, high
PDRI organs should be employed with greater caution in
this population.
Equally important is the finding of significant differences in
organ utilization across the nation as a function of center
activity and waiting times. Concern over excess wastage
of viable pancreas allografts has been voiced by several au-
thors over the past several years. Stratta, Kaper and Krieger
have all documented the underutilization of pancreas al-
lografts nationally and in particular DSAs (5,18,19). This
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practice reduces the number of organs recovered per
donor and reduces access to life-saving SPK transplants.
In part, this practice may be the result of caps on SPKs
as a result of kidney payback obligations. It appears rea-
sonable to limit the exportation of solitary pancreata from
relatively high-risk donors when they could be used suc-
cessfully as a local SPK transplant. As kidney sharing is
often limited, many pancreata which could be used for
a local SPK are discarded if allocated out of region for a
PTA or PAK. Similar variation in utilization has also been
observed in the Eurotransplant network (20). In their expe-
rience, organ acceptance can be predicted as a function
of Pancreas Suitability Score (PASS). The PASS is a com-
posite score including age, BMI, intensive care unit stay,
history of cardiacarrest, elevated sodium, amylase, lipase
and vasopressor requirement. However, unlike the PDRI,
the PASS has not been correlated with graft outcome over-
all, nor in specific transplant types. It is therefore unclear
whether these factors represent valid reasons for declining
an offered organ.
The PDRI is subject to the limitations of all registry analyses
and should be viewed as a work in progress. The donor fac-
tors here represent only those that are currently collected
through the OPTN and are subject to reporting variation
and a lack of retrospective validation. As such, other po-
tentially important variables including donor surgeon expe-
rience, donor length of hospital stay, flush volume, vaso-
pressor utilization and appearance of the gland were not
included. However, an extensive list of variables was exam-
ined and excluded based on statistical analysis including
type of preservation solution and donor amylase. Because
PTx surgeons remain conservative, the allografts available
for evaluation through the PDRI are already a highly se-
lected group, perhaps excluded based on these factors.
Therefore, the predictive value of these factors may not be
captured given the limited number of high-risks grafts that
have been previously utilized.
The PDRI does include cold ischemia time as an important
component of the index. While this is not strictly a donor
characteristic, it is driven by the location of the donor and
the intrinsic limitation of travel time. Recipient surgeons
can generally estimate logistical factors and incorporate
them into the organ acceptance decision. It is also impor-
tant to note that for applications and analyses where the
CIT is not yet known or not relevant, the PDRI can be cal-
culated using the same equation without CIT data without
any loss of utility. Under these circumstances, the CIT term
in the equation can be eliminated or set to the reference
value such that the contribution of the CIT term to the PDRI
calculation is zero. Thus, utilization of the PDRI is possible
in either allocation algorithms or simply for communica-
tion of pure donor risk at the time of organ offer. In fact,
use of the liver and kidney DRI equations, both of which
technically include CIT, are being considered for these pur-
poses by the OPTN. For the allocation and regional vari-
ation analyses in this study, the ischemia time was held
constant at 12 h, allowing an accurate reflection of region
variability.
The PDRI is also a complex interaction of multiple variables.
However, with the readily accessible technology available
through the OPTN, we anticipate that the PDRI could be
easily calculated and provided to clinicians at the time of
a specific donor offer. Equally important, patients can be
apprised of the potential impact of donor quality on the
balance between waiting time and risk of graft failure.
In summary, the PDRI was used to assess the differential
impact of organ quality on PTx outcomes within a particular
clinical scenario (SPK, PAK and PTA), between the groups
and according to recipient severity of illness. The PDRI pre-
dicted PTx graft outcome using data available at the time of
the organ offer. Increased PDRI was associated with a sig-
nificant, graded reduction in 1-year pancreas graft survival.
PDRI is a useful measure of graft quality and demonstrates
the potential value to inform organ acceptance, understand
opportunities to enhance efficiency of the organ allocation
process, and potentially improve the utilization of higher
risk organs in appropriate clinical settings.
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